Table 2.

Percent incidence rates of obesity (≥95th BMI-for-chronological-age percentile) and height-age-obesity (≥95th BMI-for-height-age percentile)

	Salt wasting	Simple virilizing
Sample size (N = 194)	124	70
Obesity (%)	47	50
Height-age-obesity (%)	43	33
Height-age-obesity at 3 or more clinic visits (%)	6	1
Height-age-obesity by birth era (%)
1970–1994 (n = 133)	45	32
1994–2013 (n = 61)	38	36
Incidence of height-age-obesity among children observed in each age interval (%)
2–5 years	18	26
6–11 years	26	11
12–18 years	6	12
Prevalence of obesity in US children (NHANES 2011–201233; %)
2–5 years	8
6–11 years	18
12–19 years	21
Incidence of height-age-obesity by hydrocortisone (HC) dose†
HC < 15 mg/m2/day	2.3 (1–5)	1.6 (0.2–12)
HC ≥ 15 mg/m2/day	2.7 (1–7)	1.3 (0.2–10)
Incidence of height-age-obesity by hydrocortisone (HC) and fludrocortisone (F) dose†
HC < 15 mg/m2/day, no F	2.4 (0.3–18)
HC ≥ 15 mg/m2/day, no F	2.3 (0.3–18)
HC < 15 mg/m2/day, with F	2.1 (1.0–5)
HC ≥ 15 mg/m2/day, with F	2.2 (0.8–6)
Age 2–5 years: Height-age-obesity by measurements of 17 OHP < 400 ng/dl‡ (%)
<3	14*
3 or more	27*
Age 6–11 years: Height-age-obesity by measurements of 17 OHP < 400 ng/dl‡ (%)
<3	19
3 or more	18

Rates were compared between CAH subtypes, between hydrocortisone and fludrocortisone dose groups and between those with <3 and 3 or more measurements of 17 OHP <400 ng/dl; there were no significant differences at the 0.05 level.

^†Values are incidence rates per 100 patient years (95% confidence interval). Restricted to children aged 2–9 years old; all SW children received fludrocortisone.

^‡Restricted to subjects with at least 3 measurements of 17-OHP; 400 ng/dl of 17OHP = 12.12 nmol/l. (ng/dl × 0.0303 = nmol/l).

^*Incidence in children with <3 such measurements trended lower (P = 0.064).